Repurposing DMF or omaveloxolone to activate Nrf2-ARE pathway, upregulating antioxidant response elements to restore lysosomal function and suppress neuroinflammation in GRN haploinsufficiency. Moderate priority with orphan drug pathway but challenged by prior Nrf2 activator failures in CNS indications.
AAV9-mediated overexpression of LAMP2A enhances chaperone-mediated autophagy to selectively degrade pathological alpha-synuclein species, preventing Lewy body formation and blocking cell-to-cell propagation. Strongest mechanistic foundation with validated AAV platform and clear patient stratification via seed amplification assays.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
AutophagyNeuroinflammationneurodegeneration
Convergent signals
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
2/11
dimensions won
Nrf2 Pathway Activation Compensates for
10/11
dimensions won
LAMP2A-Mediated Autophagy Enhancement Bl
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.65
0.80
Evidence
0.60
0.75
Novelty
0.55
0.70
Feasibility
0.65
0.75
Impact
0.60
0.80
Druggability
0.75
0.70
Safety
0.60
0.65
Competition
0.70
0.75
Data
0.55
0.80
Reproducible
0.65
0.75
KG Connect
0.50
0.50
Score Breakdown
Dimension
Nrf2 Pathway Activation Compen
LAMP2A-Mediated Autophagy Enha
Mechanistic
0.650
0.800
Evidence
0.600
0.750
Novelty
0.550
0.700
Feasibility
0.650
0.750
Impact
0.600
0.800
Druggability
0.750
0.700
Safety
0.600
0.650
Competition
0.700
0.750
Data
0.550
0.800
Reproducible
0.650
0.750
KG Connect
0.500
0.500
Evidence
Nrf2 Pathway Activation Compensates for Progranulin Haploins